Goland Sorel, Tsai Fausen, Habib Munira, Janmohamed Munir, Goodwin T Murphy, Elkayam Uri
Department of Medicine, Division of Cardiology and Department of Obstetrics and Gynecology, University of Southern California, Keck School of Medicine, Los Angeles, CA, USA.
Cardiology. 2010;115(3):205-8. doi: 10.1159/000287638. Epub 2010 Feb 18.
Pulmonary hypertension carries significant maternal and fetal risk during pregnancy and the postpartum period. As maternal mortality is high, specific targeted therapy for pulmonary hypertension may be required during pregnancy.
We describe 2 pregnant patients who presented with severe secondary pulmonary arterial hypertension during their last trimester. They were electively treated in the late antepartum and early postpartum periods with sildenafil and intravenous epoprostenol and successfully delivered healthy infants via cesarean section without postpartum complications.
Although pulmonary hypertension is associated with a risk of maternal mortality and most women are advised against pregnancy, new therapies may improve the outcome of pregnancy in patients with pulmonary hypertension.
妊娠和产后期间，肺动脉高压会给孕产妇和胎儿带来重大风险。由于孕产妇死亡率较高，孕期可能需要针对肺动脉高压进行特定的靶向治疗。
我们描述了2例在妊娠晚期出现严重继发性肺动脉高压的孕妇。她们在孕晚期和产后早期接受了选择性治疗，使用西地那非和静脉注射依前列醇，并通过剖宫产成功分娩出健康婴儿，且无产后并发症。
尽管肺动脉高压与孕产妇死亡风险相关，且大多数女性被建议避免怀孕，但新的治疗方法可能会改善肺动脉高压患者的妊娠结局。
